Twist Bioscience earnings release, August 3, 2026

Twist Bioscience Corp (TWST) · Form 8-K, Item 2.02 · Filed · SEC filing

Twist Bioscience Reports Fiscal Third Quarter 2026

Financial Results — Record revenue of $118.4 million in

3QFY26; Increase of more than 23% over $96.1 million in

3QFY25;

14th consecutive quarter of sequential growth — — Gross margin of

52.8% in

3QFY26, sequential increase of 120 basis points — — FY 2026 Revenue guidance raised to $456-$457M, an increase of $12M at the midpoint; Reiterating Q4 FY26 Adj EBITDA breakeven — SOUTH SAN FRANCISCO, Calif. --

(August 3, 2026) — Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today reported financial results and business highlights for the third quarter ended June 30, 2026.

"We continued our pattern of strong growth, reporting our fourteenth consecutive quarter of growth and exceeding guidance with revenue for the third quarter of fiscal 2026 of $118.4 million, growth of more than 23% compared to the third quarter of fiscal 2025," said Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience. "Well into our final quarter of the fiscal year, we remain confident in our trajectory and continue to expect to achieve adjusted EBITDA breakeven this quarter. That milestone is not the destination. It's the foundation for delivering disciplined execution and profitable growth as we move through fiscal 2027."

See "Non-GAAP Information" below for a discussion of the measure adjusted EBITDA.

FISCAL 2026 THIRD QUARTER FINANCIAL RESULTS

• Revenue:

Total revenues for the third quarter of fiscal 2026 grew 23% to $118.4 million compared to $96.1 million for the same period of fiscal 2025.

◦ DNA Synthesis and Protein Solutions (DSPS) revenue grew

39% to $56.6 million for the third quarter of fiscal 2026 compared to $40.8 million for the same period of fiscal 2025, and grew 6% sequentially, compared to $53.3 million for the second quarter of fiscal 2026.

◦ NGS Applications (NGS) revenue grew 12% to $61.8 million for the third quarter of fiscal 2026 compared to $55.3 million for the same period of fiscal 2025, and grew 8% sequentially, compared to $57.4 million for the second quarter of fiscal 2026.

• Cost of Revenues:

Cost of revenues for the third quarter of fiscal 2026 increased to $55.9 million compared to $44.8 million for the same period of fiscal 2025.

• Gross Margin

: Gross margin for the third quarter of fiscal 2026 was 52.8%, up sequentially from 51.6% in the second quarter of fiscal 2026.

• Research and Development Expenses:

Research and development expenses for the third quarter of fiscal 2026 were $18.0 million consistent with $18.0 million for the same period of fiscal 2025.

• Selling, General and Administrative Expenses:

Selling, general and administrative expenses for the third quarter of fiscal 2026 were $80.7 million compared to $63.4 million for the same period of fiscal 2025.

• Net (Loss) Income:

Net loss for the third quarter of fiscal 2026 increased to $35.1 million, or $0.56 per diluted share, compared to net income of $20.4 million, or

$0.33 per diluted share, for the same period of fiscal 2025. The third quarter of fiscal 2025 included a gain of $48.8 million from the spin out of Atlas Data Storage.

• Adjusted EBITDA:

Adjusted EBITDA for the third quarter of fiscal 2026 was $(11.3) million compared to $(8.0) million for the same period of fiscal 2025. See the table included in this release for a reconciliation between adjusted EBITDA, and net (loss) income attributable to common stockholders, the most directly comparable GAAP financial measure.

• Ca sh Position:

As of June 30, 2026, the company had approximately

$167 million in cash, cash equivalents and short-term investments.

Recent Highlights:

• Shipped products to approximately

2,650 customers in the third quarter of fiscal 2026, versus approximately

2,480 in the same period of fiscal 2025.

• Physically shipped approximately

369,000 genes in the third quarter of fiscal 2026, plus consecutive quarter over quarter growth in genes manufactured for data characterization compared with approximately

237,000 in the same period of fiscal 2025.

• Hosted inaugural Investor Day at the Twist Wilsonville, OR site.

• Twist Comprehensive Viral Research Panel enabled researchers in the Democratic Republic of the Congo to identify a rare strain of Ebola that PCR tests missed.

• Following early access period, launched Twist Complex Genes commercially for broad access.

Fiscal 2026 Financial Guidance

Financial statements

Income Statement

Three months ended June 30, — (in thousands) (In thousands, except per share data)

Three months ended June 30, – 2026Three months ended June 30, – 2025Nine months ended June 30, – 2026Nine months ended June 30, – 2025
Revenues118,37696,057332,789277,563
Costs and expenses:Cost of revenues55,92244,760159,241137,398
Costs and expenses:Research and development expenses18,02518,04754,85063,271
Costs and expenses:Selling, general and administrative expenses80,70963,370226,536183,219
Costs and expenses:Litigation settlement costs, net of recoveries7,205
Costs and expenses:Total costs and expenses154,656126,177447,832383,888
Costs and expenses:Loss from operations-36,280-30,120-115,043-106,325
Costs and expenses:Gain on sale of business48,847$—48,847
Costs and expenses:Interest income1,5002,6905,3858,731
Costs and expenses:Other income (expense), net40-836686-1,323
Costs and expenses:Income tax expense-311-191-607-462
Costs and expenses:Net (loss) income-35,05120,390-109,579-50,532
Costs and expenses:Net (loss) income per share — basic-0.560.34-1.78-0.85
Costs and expenses:Weighted average shares used in computing net (loss) income per share — basic62,40359,99561,72659,600
Costs and expenses:Net (loss) income per share — diluted-0.560.33-1.78-0.85
Costs and expenses:Weighted average shares used in computing net (loss) income per share —diluted62,40361,16461,72659,600

Income Statement

Three months ended June 30, (in thousands)

Three months ended June 30, – 2026Three months ended June 30, – 2025Nine months ended June 30, – 2026Nine months ended June 30, – 2025
GAAP net (loss) income-35,05120,390-109,579-50,532
Add (Deduct) adjustments:Interest income-1,500-2,690-5,385-8,731
Add (Deduct) adjustments:Income tax expense311191607462
Add (Deduct) adjustments:Depreciation and amortization6,7786,06519,38618,849
Add (Deduct) adjustments:EBITDA-29,46223,956-94,971-39,952
Add (Deduct) adjustments:Litigation settlement costs, net of recoveries7,205$—
Add (Deduct) adjustments:Gain on sale of business-48,847-48,847
Add (Deduct) adjustments:Other (income) expense, net-40836-6861,323
Add (Deduct) adjustments:Stock-based compensation expense18,17616,05750,38548,376
Add (Deduct) adjustments:Adjusted EBITDA-11,326-7,998-38,067-39,100

Balance Sheet

June 30, 2026 — (in thousands)

June 30, 2026September 30, 2025
Cash and cash equivalents117,436183,049
Short-term investments49,40349,385
Accounts receivable, net65,05557,019
Inventories35,16228,309
Prepaid expenses and other current assets54,23915,204
Total current assets321,295332,966
Property and equipment, net111,888102,283
Operating lease right-of-use assets68,73649,377
Investment in equity securities68,08754,337
Other non-current assets102,432102,898
Total assets672,437641,861
Current liabilities:Accounts payable17,04311,094
Current liabilities:Accrued compensation34,87931,288
Current liabilities:Current portion of operating lease liability8,63013,822
Current liabilities:Other current liabilities59,70335,202
Current liabilities:Total current liabilities120,25591,406
Current liabilities:Operating lease liability, net of current portion84,96061,750
Current liabilities:Liability related to the sale of future revenue15,00015,000
Current liabilities:Other non-current liabilities6,483747
Current liabilities:Total liabilities226,698168,903
Current liabilities:Total stockholders’ equity445,739472,958
Current liabilities:Total liabilities and stockholders’ equity672,437641,861
Full release

The following statements are based on Twist’s current expectations for fiscal 2026. The following statements are forward-looking, and actual results could differ materially depending on market conditions and the factors set forth under “Forward-Looking Statements” below.

For the full fiscal year 2026, Twist expects

:

• Total revenue in the range of $456 million to $457 million, growth of approximately 21% year over year, compared to prior guidance of $442 to $447 million.

• Gross margin to be above 52%.

For the fourth quarter, Twist expects:

• Total revenue of approximately $123 million to $124 million, growth of approximately 25% yea r over year at the midpoint, with sequential growth in both DSPS and NGS Applications.

• To achieve adjusted EBITDA breakeven.

Non-GAAP Information... (truncated)cial measures, when considered together with our financial information prepared in accordance with GAAP, can enhance investors’ and analysts’ ability to meaningfully compare our results from period to period and to our forward-looking guidance, and to identify operating trends in our business. However, non-GAAP information is not superior to financial measures calculated in accordance with GAAP, is presented for supplemental informational purposes only, has limitations as an analytical tool and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. A reconciliation table of the most comparable GAAP financial measure to the non-GAAP financial measures is included at the end of this press release.

A reconciliation of adjusted EBITDA for the fourth quarter of fiscal 2026 to a corresponding GAAP financial guidance measure is not available on a forward-looking basis because the Company does not provide guidance on GAAP net (loss) income and is not able to present the various reconciling cash and non-cash items between GAAP net (loss) income and adjusted EBITDA without unreasonable effort. In particular, stock-based compensation expense is impacted by the Company’s future hiring and retention needs, as well as the future fair market value of its common stock, all of which is difficult to predict and is subject to change. The actual amount of these expenses during the fourth quarter of fiscal 2026 will have a significant impact on Twist’s future GAAP financial results.

Conference Call Information

The company plans to hold a conference call and live audio webcast for analysts and investors at 8:00 a.m. Eastern Time today to discuss its financial results and provide an update on the company’s business. The conference call will be webcast live through the Investor Relations section under the “Company” tab at www.twistbioscience.com. Those parties interested in participating via telephone must register on the Company’s Investor Relations website or by clicking here. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN number that can be used to access the call. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The webcast replay will be available for two weeks.

About Twist Bioscience

At Twist Bioscience, our customizable solutions across the biological continuum raise the bar in diagnostics, therapeutics, industrial, agriculture and research markets.

We drive innovation with confidence, without compromise. Whether delivering oligos, genes, proteins, libraries, characterization data, antibody discovery solutions, or NGS workflow tools, our scientific expertise and exceptional customer experience help navigate complex challenges, all with precision and at the scale and speed customers require. By enhancing R&D efficiency at every turn, we give scientists more shots on goal – more experiments, more iterations, more chances for remarkable discoveries.

Together, we stand with customers in the relentless pursuit of progress, backed by enterprise reliability, to shape a healthier and more sustainable future for all. For more information about our products and services, please visit www.twistbioscience.com.

Follow us on LinkedIn |

X | YouTube

Instagram

Bluesky

Legal Notice Regarding Forward-Looking Statements

This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, projections under the heading “Fiscal 2026 Financial Guidance,” statements regarding future growth and expansion in future fiscal periods, including fiscal 2027, drivers of future revenue and gross margin growth, including expected growth of AI-enabled discovery and projected serviceable market, estimated annual revenues, ability and timing to achieve profitability, ability and timing to achieve adjusted EBITDA breakeven and ability to maintain or increase gross margins and Twist’s other expectations regarding its future operations plans and financial performance, introduction of new products, and newly announced partnerships. Forward-looking statements involve known and unknown risks, uncertainties, and other important factors that may cause Twist’s actual results, performance, or achievements to be materially different from any future results, performance, or achievements expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the ability to attract new customers and retain and grow sales from existing customers; the ability of Twist to achieve sufficient revenue to achieve or maintain positive cash flow from operations or profitability in any given period; risks and uncertainties of rapidly changing technologies and extensive competition in synthetic biology that could make the products Twist is developing obsolete or non-competitive; the ability to integrate and leverage artificial intelligence and machine learning technologies to improve operational efficiency, product development, and customer solutions; the ability to expand DNA synthesis manufacturing capacity; dependence on one supplier for a critical component; dependence on key personnel; additional regulations that could increase Twist’s costs and delay commercialization efforts; changes in U.S. trade policies and other trade actions that could result in increased costs and supply chain disruptions; risks associated with the spin out of Atlas Data Storage; the ability to maintain and enforce intellectual property protection; uncertainty as to economic and market conditions and the impact of adverse economic conditions; and the ability to obtain financing when necessary. For a description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to Twist’s business in general, see Twist’s risk factors set forth in Twist’s Annual Report on Form 10-K filed with the Securities and Exchange Commission on November 17, 2025. Any forward-looking statements contained in this press release speak only as of the date hereof, and Twist specifically disclaims any obligation to update any forward-looking statement, whether as a result of new information, future events or otherwise.

For Investors:

Angela Bitting

SVP, Corporate Affairs

925-202-6211 abitting@twistbioscience.com

For Media:

Amanda Houlihan

Communications Manager

774-265-5334 ahoulihan@twistbioscience.com

Twist Bioscience Corporation

Condensed Consolidated Statements of Operations

(Unaudited)

(in thousands)

Twist Bioscience Corporation

Condensed Consolidated Balance Sheets

(Unaudited)

(in thousands)

Twist Bioscience Corporation

Adjusted EBITDA

(Unaudited)

(in thousands)

The following table sets forth a reconciliation between our Adjusted EBITDA and net (loss) income attributable to common stockholders, the most directly comparable GAAP financial measure, for each of the periods presented:

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.